Exclusive: FTC Expected To Make Mylan-Upjohn Announcement Today
FTC Approval A Major Hurdle To Deal Completion
Executive Summary
Almost 500 days after the transaction was first announced, Viatris, the proposed combination of Mylan and Pfizer’s Upjohn, is set to receive word from the US Federal Trade Commission, representing the last major obstacle to getting the deal over the line.
You may also be interested in...
Mylan And Upjohn Combination Takes Key Step To Completion
Shortly after agreeing to divest three mature Upjohn brands in Australia, Mylan and the Pfizer off-patent and mature brands unit have stepped closer to merging into Viatris, bagging another key regulatory approval that had been in the works for several months.
Mylan Strikes €642m Deal For Aspen’s Thrombosis Business In Europe
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
Mylan And Pfizer Announce Key Date For Viatris Merger
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.